Rhelion Life Sciences Corp. (CSE: RHEL; OTCQB: TRUFF; FSE: 4YX0) announced on August 27, 2026, that its wholly owned subsidiary Filament Health added a new U.S. patent covering a natural-source psychoactive alkaloid extraction process.
U.S. Patent No. 12,697,564, titled “Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids,” was issued on August 4. The patent names Filament subsidiary Psilo Scientific Ltd. as the filer and contains 16 claims.
The protected process involves extracting psychoactive alkaloids from fungal biomass using an acidified methanol-and-water solution. The resulting extract can then be concentrated and standardized to produce a consistent amount of the targeted compounds.
That consistency is important when a drug candidate originates from biological material that can vary between crops. Filament uses proprietary extraction, purification and stabilization methods to manufacture PEX010, its standardized botanical psilocybin candidate.
The patent protects a specific manufacturing process. It does not provide exclusivity over every psilocybin product or extraction method, nor does it establish that PEX010 is safe or effective.
According to Rhelion’s announcement, the company’s portfolio now includes 77 issued patents across 13 patent families. Those patents cover areas such as extraction, purification, stabilization, standardized compositions and drug delivery. The portfolio total and Rhelion’s claim that it holds the broadest natural-psilocybin patent estate have not been independently verified.
Rhelion CEO Todd Shapiro said Filament’s patents protect “how the drug candidate is made, at scale, to GMP.” The company acquired Filament on April 30, bringing PEX010, its manufacturing infrastructure and its clinical-research network under Rhelion.
PEX010 is available in 1-milligram, 5-milligram and 25-milligram doses, with a 0.5-milligram formulation planned. Rhelion says the candidate is supporting more than 80 academic and philanthropic studies worldwide.
On August 25, Filament announced that it had shipped PEX010 for an investigator-initiated Phase 2a study at the University of Washington. The study will evaluate group-based psilocybin therapy for anxiety and depression in people with metastatic solid tumors or incurable blood cancers. Filament is supplying the study drug but is not the trial sponsor.
Rhelion, then operating as Red Light Holland, reported C$8.47 million in cash and C$4.20 million in fiscal 2026 revenue as of March 31. Its adjusted EBITDA loss widened to C$2.93 million. Those figures predate the Filament acquisition and do not represent a full reporting period for the combined company.
Upcoming Catalysts
- Availability of the planned 0.5-milligram PEX010 formulation
- Additional patent grants or licensing agreements
- Progress from investigator-initiated studies using PEX010
- Financial results reflecting the combined Rhelion and Filament business
- Regulatory developments involving PEX010 clinical programs
Sources
- Rhelion announces new U.S. patent — August 27, 2026
- USPTO Patent No. 12,697,564 — August 4, 2026
- PEX010 shipment for University of Washington Phase 2a study — August 25, 2026
- Rhelion fiscal 2026 financial and operational results — July 29, 2026
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, patent records, regulatory filings and publicly available corporate sources. Securities discussed or referenced include Rhelion Life Sciences Corp. (CSE: RHEL; OTCQB: TRUFF; FSE: 4YX0). Biotech Stocks Daily has not received compensation from Rhelion Life Sciences, Filament Health, their management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Confirmed sources include Rhelion’s August 27, 2026 patent announcement, the official USPTO patent record, its August 25, 2026 University of Washington clinical-supply announcement and the company’s fiscal 2026 financial results. Statements concerning the size, comparative breadth and commercial value of Rhelion’s patent portfolio originated from the company and have not been independently validated by Biotech Stocks Daily.
PEX010 remains investigational and has not been approved for commercial sale. An issued patent does not establish clinical safety, efficacy or regulatory acceptance. Patents may be challenged, narrowed, invalidated or designed around and may not produce a material competitive or commercial benefit. Clinical studies involving PEX010 may encounter enrollment, regulatory, safety or operational delays and may not generate favorable results.
Financial information reflects Rhelion’s position as of March 31, 2026, is reported in Canadian dollars and predates its April 30 acquisition of Filament Health. The figures do not represent a full reporting period for the combined business. No real-time securities prices are included, and readers should verify current market and financial information independently.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
